RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RAPT Therapeutics - Stock

RAPT Therapeutics EBIT 2024

RAPT Therapeutics EBIT

-116.45 M USD

Ticker

RAPT

ISIN

US75382E1091

WKN

A2PNYQ

In 2024, RAPT Therapeutics's EBIT was -116.45 M USD, a -8.35% increase from the -127.06 M USD EBIT recorded in the previous year.

The RAPT Therapeutics EBIT history

YEAREBIT (undefined USD)
2029e-
2028e-
2027e-
2026e-
2025e-
2024e-
2023-
2022-
2021-
2020-
2019-
2018-
2017-

RAPT Therapeutics Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • Max

Revenue
EBIT
Net Income
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into RAPT Therapeutics, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by RAPT Therapeutics from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects RAPT Therapeutics’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of RAPT Therapeutics. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into RAPT Therapeutics’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing RAPT Therapeutics’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on RAPT Therapeutics’s growth potential.

RAPT Therapeutics Revenue, EBIT and net profit per share

DateRAPT Therapeutics RevenueRAPT Therapeutics EBITRAPT Therapeutics Net Income
2029e303.01 M undefined0 undefined27.69 M undefined
2028e155.58 M undefined-358.02 M undefined-76.49 M undefined
2027e88.23 M undefined-302.94 M undefined-132.4 M undefined
2026e25.14 M undefined-142.11 M undefined-70.64 M undefined
2025e0 undefined-117.4 M undefined-69.97 M undefined
2024e0 undefined-116.45 M undefined-93.63 M undefined
20230 undefined-127.06 M undefined-116.8 M undefined
20221.53 M undefined-85.8 M undefined-83.84 M undefined
20213.81 M undefined-69.21 M undefined-69.2 M undefined
20205.04 M undefined-53.21 M undefined-52.89 M undefined
20190 undefined-43.63 M undefined-43 M undefined
20180 undefined-36.95 M undefined-36.15 M undefined
20170 undefined-29.33 M undefined-29.12 M undefined

RAPT Therapeutics stock margins

The RAPT Therapeutics margin analysis displays the gross margin, EBIT margin, as well as the profit margin of RAPT Therapeutics. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for RAPT Therapeutics.

  • 3 years

  • 5 years

  • 10 years

  • Max

Gross margin
EBIT margin
Profit margin
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the RAPT Therapeutics's sales revenue. A higher gross margin percentage indicates that the RAPT Therapeutics retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the RAPT Therapeutics's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the RAPT Therapeutics's total revenue generated. When comparing the revenue margin year over year, investors can gauge the RAPT Therapeutics's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the RAPT Therapeutics. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the RAPT Therapeutics's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

RAPT Therapeutics Margin History

RAPT Therapeutics Gross marginRAPT Therapeutics Profit marginRAPT Therapeutics EBIT marginRAPT Therapeutics Profit margin
2029e0 %0 %9.14 %
2028e0 %-230.12 %-49.17 %
2027e0 %-343.35 %-150.06 %
2026e0 %-565.19 %-280.94 %
2025e0 %0 %0 %
2024e0 %0 %0 %
20230 %0 %0 %
20220 %-5,607.84 %-5,479.74 %
20210 %-1,816.54 %-1,816.27 %
20200 %-1,055.75 %-1,049.4 %
20190 %0 %0 %
20180 %0 %0 %
20170 %0 %0 %

RAPT Therapeutics Aktienanalyse

What does RAPT Therapeutics do?

Rapt Therapeutics Inc. is an emerging pharmaceutical company that was originally founded in 2015 under the name "FLX Bio". The company is based in San Francisco, California. Rapt is the name of the biological process that the company uses to identify and develop drug candidates. Rapt Therapeutics specializes in developing innovative immunotherapies for cancer treatment. The goal is to harness the power of the immune system to support the body in fighting cancer. The company focuses on developing prophylactic cancer vaccines and immunotherapies that aim to directly combat cancer cells and strengthen the body's defenses. The company's business model is based on an innovative technology platform that is able to identify antibodies and other molecules that activate the RAPT process, which is important for combating cancer cells. With this technology, Rapt Therapeutics can quickly and accurately identify potential drug candidates that are suitable for the development of cancer immunotherapies. At the time of its founding, Rapt primarily focused on developing immunotherapeutics for solid tumors, a type of cancer that originates in a specific tissue in the body and does not spread to adjacent tissues or organs. However, the company has since expanded its portfolio to include the development of therapeutics for hematological cancers such as leukemia and lymphoma. Rapt Therapeutics employs a pipeline-based research strategy. The pipeline-based research strategy means that Rapt Therapeutics develops a variety of drug candidates targeting different disease indications. The drug candidates are then tested in different phases of clinical development to evaluate their efficacy and safety. To date, Rapt Therapeutics has four drug candidates in clinical development. The first candidate, RPT193, is currently being tested in phase 1 clinical trials for the treatment of various solid tumors. The second candidate, RPT835, is currently in preclinical development and targets the treatment of leukemia. The third candidate, FLX475, is also in preclinical development and targets the treatment of multiple sclerosis. The fourth candidate, FLX475, is currently in phase 1 clinical trials and targets the treatment of certain solid tumors. In addition, Rapt Therapeutics has also entered into a number of partnerships with other pharmaceutical companies. In 2018, Rapt Therapeutics signed a strategic collaboration with AstraZeneca to accelerate the development of RPT193. Under this collaboration, AstraZeneca will test RPT193 in clinical trials. In 2019, Rapt Therapeutics entered into a research and development collaboration with Hanmi Pharmaceutical Co. Ltd. to accelerate the discovery, development, and commercialization of drug candidates for cancer and other diseases. Rapt Therapeutics is pursuing a long-term strategy to become a leading company in immunotherapy development. By continuing its research and development of cancer immunotherapies, Rapt has the potential to improve the lives of millions of people suffering from cancer and other serious diseases. RAPT Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

EBIT Details

Analyzing RAPT Therapeutics's EBIT

RAPT Therapeutics's Earnings Before Interest and Taxes (EBIT) represents the company's operating profit. It is calculated by deducting all operating expenses, including the cost of goods sold (COGS) and operating expenses, from the total revenue, but before accounting for interest and taxes. It provides insights into the company’s operational profitability, excluding the impacts of financing and tax structures.

Year-to-Year Comparison

A yearly comparison of RAPT Therapeutics's EBIT can reveal trends in the company’s operational efficiency and profitability. An increase in EBIT over the years can indicate enhanced operational efficiency or growth in revenue, while a decrease might raise concerns about increased operating costs or declining sales.

Impact on Investments

RAPT Therapeutics's EBIT is a significant metric for investors. A positive EBIT suggests that the company is generating enough revenue to cover its operating expenses, an essential aspect for assessing the company’s financial health and stability. Investors closely monitor EBIT to gauge the company’s profitability and potential for future growth.

Interpreting EBIT Fluctuations

Fluctuations in RAPT Therapeutics’s EBIT can be due to variations in revenue, operating expenses, or both. An increasing EBIT indicates improved operational performance or increased sales, while a declining EBIT can signal rising operational costs or reduced revenue, prompting a need for strategic adjustments.

Frequently Asked Questions about RAPT Therapeutics stock

How much did RAPT Therapeutics achieve in EBIT for the current year?

In the current year, RAPT Therapeutics has achieved an EBIT of -116.45 M USD.

What is EBIT?

EBIT stands for Earnings Before Interest and Taxes and refers to the profit before interest and taxes of a company RAPT Therapeutics.

How has the EBIT of RAPT Therapeutics developed in recent years?

The EBIT of RAPT Therapeutics has increased by -8.353% decreased compared to the previous year.

What does EBIT mean for investors?

EBIT provides investors with insights into a company's profitability as it reflects the profit before interest expenses and taxes.

Why is EBIT an important indicator for investors?

Since EBIT provides a more direct insight into a company's profit than net income, it is an important indicator for investors to assess the profitability of a company.

Why do EBIT values fluctuate?

EBIT values can fluctuate as they are influenced by various factors, such as revenue, costs, and tax effects.

What role does tax burden play in EBIT?

Tax burdens have a direct impact on a company's EBIT, as they are deducted from the profit.

How is EBIT presented in the balance sheet of the company RAPT Therapeutics?

The EBIT of RAPT Therapeutics is listed in the income statement.

Can EBIT be used as a single indicator for evaluating a company?

EBIT is an important indicator for evaluating a company, but additional financial ratios should also be considered to get a comprehensive picture.

Why is EBIT not equal to net profit?

The net profit of a company includes taxes and interest, while EBIT represents the profit before interest and taxes.

How much dividend does RAPT Therapeutics pay?

Over the past 12 months, RAPT Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RAPT Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of RAPT Therapeutics?

The current dividend yield of RAPT Therapeutics is .

When does RAPT Therapeutics pay dividends?

RAPT Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RAPT Therapeutics?

RAPT Therapeutics paid dividends every year for the past 0 years.

What is the dividend of RAPT Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RAPT Therapeutics located?

RAPT Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von RAPT Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RAPT Therapeutics from 7/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.

When did RAPT Therapeutics pay the last dividend?

The last dividend was paid out on 7/7/2024.

What was the dividend of RAPT Therapeutics in the year 2023?

In the year 2023, RAPT Therapeutics distributed 0 USD as dividends.

In which currency does RAPT Therapeutics pay out the dividend?

The dividends of RAPT Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The RAPT Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von RAPT Therapeutics

Our stock analysis for RAPT Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RAPT Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.